Full Text Journal Articles in
Journal J. Natl. Cancer Inst.

Advertisement

Find full text journal articles






Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.

Stanley L Liauw, Sandra A Ham, Lauren C Das, Sonali Rudra, Vignesh Packiam, Matthew Koshy, Ralph R Weichselbaum, Yolanda T Becker, Adam Bodzin, Scott E Eggener,

BACKGROUND:Immunosuppressive regimens associated with organ transplantation increase the risk of developing cancer. Transplant candidates and recipients with prostate cancer are often treated, even if low risk features would ordinarily justify active surveillance. METHODS:Using SEER-Medicare, we identified 163,676 men aged ≥66, diagnosed with non-metastatic prostate cancer. History of solid organ transplant ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer.

Holly Sarvas, Benjamin Carlisle, Samantha Dolter, Esther Vinarov, Jonathan Kimmelman,

Precision medicine offers opportunities for reducing the costs, burdens, and time associated with drug development. We examined time, number of trials, indications tested and patient burden needed to achieve first FDA license for all 5 novel anti-cancer precision-medicine drugs and all 10 novel non-precision medicine drugs receiving FDA approval 2010-2014. ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Factors associated with utilization of high cost agents for the treatment of metastatic non-small cell lung cancer.

Cathy J Bradley, Megan Eguchi, Marcelo C Perraillon,

BACKGROUND:Antineoplastic agents approved in recent decades are a marked advancement in cancer treatment but come at considerable cost. These drugs may widen survival disparities between patients who receive these agents and those who do not. We examine factors associated with the utilization of high cost antineoplastic agents for the treatment ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Efficacy of the AS04-adjuvanted HPV-16/18 vaccine: Pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials.

Joseph E Tota, Frank Struyf, Joshua N Sampson, Paula Gonzalez, Martin Ryser, Rolando Herrero, John Schussler, Naveen Karkada, Ana Cecilia Rodriguez, Nicolas Folschweiller, Carolina Porras, Mark Schiffman, John T Schiller, Wim Quint, Aimée R Kreimer, Cosette M Wheeler, Allan Hildesheim, , ,

BACKGROUND:The AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine provides excellent protection against targeted HPV types and a variable degree of cross-protection against others, including types 6/11/31/33/45. High efficacy against any cervical intraepithelial neoplasia grade 3 or greater (CIN3+; >90%) suggests lower levels of protection may exist for a wide-range of oncogenic HPV types, ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Corrigendum.

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.

Jessie Torgersen, Michael J Kallan, Dena M Carbonari, Lesley S Park, Rajni L Mehta, Kathryn D'Addeo, Janet P Tate, Joseph K Lim, Matthew Bidwell Goetz, Maria C Rodriguez-Barradas, Cynthia L Gibert, Norbert Bräu, Sheldon T Brown, Jason A Roy, Tamar H Taddei, Amy C Justice, Vincent Lo Re,

BACKGROUND:Despite increasing incidence of hepatocellular carcinoma (HCC) among HIV-infected patients, it remains unclear if HIV-related factors contribute to development of HCC. We examined if higher or prolonged HIV viremia and lower CD4+ cell percentage were associated with HCC. METHODS:We conducted a cohort study of HIV-infected individuals who had HIV RNA, ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does It Matter?

Adam Brufsky, Aju Mathew,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay.

Freija Verdoodt, Christian Dehlendorff, Marja Jäättelä, Robert Strauss, Anton Pottegård, Jesper Hallas, Søren Friis, Susanne K Kjaer,

Antihistamines with cationic amphiphilic drug (CAD) characteristics induce cancer-specific cell death in experimental studies. Epidemiologic evidence is, however, limited. In a Danish nationwide cohort of ovarian cancer patients diagnosed during 2000-2015 (n = 5075), we evaluated the association between antihistamine prescriptions and cancer mortality. We used Cox regression models to estimate hazard ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Changes in noninsurance and care unaffordability among cancer survivors following the Affordable Care Act.

Xuesong Han, Ahmedin Jemal, Zhiyuan Zheng, Ann Goding Sauer, Stacey Fedewa, K Robin Yabroff,

BACKGROUND:Little is known about changes in socioeconomic disparities in noninsurance and care unaffordability among non-elderly cancer survivors following the Affordable Care Act (ACA). METHODS:Cancer survivors aged 18-64 years nationwide were identified from Behavioral Risk Factor Surveillance System. Trend and difference-in-differences (DD) analyses were conducted to examine changes in percent uninsured ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Talking the talk about tumor genomic testing.

Richard L Schilsky,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Factors associated with oncologist discussions of the costs of genomic testing and related treatments.

K Robin Yabroff, Jingxuan Zhao, Janet S de Moor, Helmneh M Sineshaw, Andrew N Freedman, Zhiyuan Zheng, Xuesong Han, Ashish Rai, Carrie N Klabunde,

BACKGROUND:Use of genomic testing is increasing in the United States. Testing can be expensive, and not all tests and related treatments are covered by health insurance. Little is known about how often oncologists discuss costs of testing and treatment, or about the factors associated with those discussions. METHODS:We identified 1220 ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Serenai Di Cosimo, Valter Torri, Luca Porcu,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1232-1233]

Cited: 0 times

View full text PDF listing >>



TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.

Utpal K Mukhopadhyay, Chetan C Oturkar, Christina Adams, Nadi Wickramasekera, Sanjay Bansal, Rajesh Medisetty, Austin Miller, Wendy M Swetzig, Laxmi Silwal-Pandit, Anne-Lise Børresen-Dale, Chad J Creighton, Jun Hyoung Park, Santhi D Konduri, Alka Mukhopadhyay, Alexander Caradori, Angela Omilian, Wiam Bshara, Benny Abraham Kaipparettu, Gokul M Das,

BACKGROUND:Anti-tumorigenic vs pro-tumorigenic roles of estrogen receptor-beta (ESR2) in breast cancer remain unsettled. We investigated the potential of TP53 status to be a determinant of the bi-faceted role of ESR2 and associated therapeutic implications for triple negative breast cancer (TNBC). METHODS:ESR2-TP53 interaction was analyzed with multiple assays including the in ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1202-1215]

Cited: 2 times

View full text PDF listing >>



Medicaid Insurance Coverage Disruptions and Stage of Disease at Diagnosis Among Adolescent and Young Adult Cancer Patients.

K Robin Yabroff, Xuesong Han, Leticia Nogueira, Ahmedin Jemal,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1111-1113]

Cited: 0 times

View full text PDF listing >>



Association of Indoor Tanning Exposure With Age at Melanoma Diagnosis and BRAF V600E Mutations.

Toni E Burbidge, Boris C Bastian, Danny Guo, Haocheng Li, Don G Morris, Jose G Monzon, Gabriella Leung, Huiming Yang, Tina Cheng,

There is limited information on how indoor tanning promotes melanoma development. We investigated indoor tanning use in patients with melanomas in sun-exposed skin and studied the clinicopathological and molecular characteristics in relation to indoor tanning exposure. Patients from a multidisciplinary clinic for cutaneous cancers completed standardized questionnaires on risk factors ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1228-1231]

Cited: 0 times

View full text PDF listing >>



Corrigendum.

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1239]

Cited: 0 times

View full text PDF listing >>



Corrigendum.

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1237]

Cited: 0 times

View full text PDF listing >>



Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.

Andrea Gini, Reinier G S Meester, Homa Keshavarz, Kevin C Oeffinger, Sameera Ahmed, David C Hodgson, Iris Lansdorp-Vogelaar,

BACKGROUND:Childhood cancer survivors (CCS) are at increased risk of developing colorectal cancer (CRC) compared to the general population, especially those previously exposed to abdominal or pelvic radiation therapy (APRT). However, the benefits and costs of CRC screening in CCS are unclear. In this study, we evaluated the cost-effectiveness of early-initiated ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1161-1169]

Cited: 0 times

View full text PDF listing >>



Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.

Maria-Athina Altzerinakou, Laurence Collette, Xavier Paoletti,

BACKGROUND:In the era of molecularly targeted agents (MTAs), it is recommended to account for toxicity over several cycles to identify the recommended phase II dose (RP2D). We investigated the relationship between the risk of toxicity at cycle 1 and the cumulative incidence of toxicity over subsequent cycles in trials of ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1179-1185]

Cited: 0 times

View full text PDF listing >>



Microenvironmental heterogeneity among triple negative breast cancer subtypes and the promise of precision medicine.

Lior Z Braunstein, Nadeem Riaz,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Corrigendum.

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1240]

Cited: 0 times

View full text PDF listing >>



Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.

Aaron J Franke, William Paul Skelton, Jason S Starr, Hiral Parekh, James J Lee, Michael J Overman, Carmen Allegra, Thomas J George,

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United States. Although immunotherapy has dramatically changed the landscape of treatment for many advanced cancers, the benefit in CRC has thus far been limited to patients with microsatellite instability high (MSI-H):DNA mismatch repair-deficient (dMMR) tumors. Recent studies in ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1131-1141]

Cited: 0 times

View full text PDF listing >>



Reporting Standards for Patient-Reported Outcomes in Clinical Trial Protocols and Publications.

Ethan Basch, Allison Barz Leahy,

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1116-1117]

Cited: 0 times

View full text PDF listing >>



Impact of Health Insurance on Stage at Cancer Diagnosis Among Adolescents and Young Adults.

Theresa H M Keegan, Helen M Parsons, Yi Chen, Frances B Maguire, Cyllene R Morris, Arti Parikh-Patel, Kenneth W Kizer, Ted Wun,

BACKGROUND:Uninsured adolescents and young adults (AYAs) and those with publicly funded health insurance are more likely to be diagnosed with cancer at later stages. However, prior population-based studies have not distinguished between AYAs who were continuously uninsured from those who gained Medicaid coverage at the time of cancer diagnosis. METHODS:AYA ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1152-1160]

Cited: 0 times

View full text PDF listing >>



Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.

Derek A Oldridge, Bao Truong, Douglas Russ, Steven G DuBois, Zalman Vaksman, Yael P Mosse, Sharon J Diskin, John M Maris, Katherine K Matthay,

BACKGROUND:Neuroblastoma is a biologically and clinically heterogeneous disease. Based on recent studies demonstrating an association between the primary tumor site, prognosis, and commonly measured tumor biological features, we hypothesized that neuroblastomas arising in different sites would show distinct genomic features reflective of the developmental biology of the sympathicoadrenal nervous system. ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2019, 111(11):1192-1201]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.5992 s